SEATTLE GENETICS INC /WA SGEN Cash Flow

Seattle genetics inc /wa (SGEN)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10	Jun'10	Mar'10
Operating activities:
Net loss
-313,723	-158,650	-304,285	-279,818	-124,307	-222,693	-162,089	-44,622	-177,255	-125,530	-121,467	-203,240	-179,623	-140,111	-109,829	-104,515	-119,274	-120,486	-122,314	-111,442	-81,530	-76,141	-65,128	-73,248	-62,557	-62,520	-57,445	-47,411	-57,748	-53,782	-70,351	-97,384	-131,654	-152,030	-159,411	-153,582	-110,399	-66,265	0	0	0
Adjustments to reconcile net loss to net cash used by operating activities
Share-based compensation
135,202	127,300	105,479	98,417	87,777	78,900	69,069	64,162	66,173	63,800	63,325	60,179	54,754	52,471	50,161	48,549	46,283	41,836	40,321	39,452	39,050	40,619	38,807	36,759	34,104	31,406	29,048	27,089	25,845	25,340	23,873	23,091	21,817	19,984	18,252	16,498	15,414	14,330	0	0	0
Depreciation and amortization
23,655	23,774	22,517	22,615	25,254	26,032	25,537	27,376	26,349	24,269	21,157	19,603	18,588	18,034	17,015	16,116	15,312	14,505	14,142	13,626	13,076	12,490	11,666	10,673	9,725	8,615	7,654	6,977	6,392	6,159	5,953	5,422	4,789	4,170	3,717	3,643	3,621	3,562	0	0	0
Amortization of right-of-use assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of premiums, accretion of discounts, and (gains) losses on debt securities
0	-	-	-	0	-	-	-	-	-497	-1,081	-964	-4,239	-4,746	-6,155	-5,957	-4,881	-2,846	-194	38	174	150	-1,018	-1,174	-1,441	-1,883	-2,334	-2,791	-2,901	-2,574	-11,038	-11,365	-12,094	-12,474	-3,687	-3,206	-2,858	-3,429	0	0	0
(Gains) losses on equity securities
-47,080	50,124	-65,804	-83,879	26,636	7,336	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent and other long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-772	-	-1,049	-1,009	-951	-921	-832	-769	-733	-734	-826	-685	-697	-606	482	540	318	716	1,552	1,934	2,523	2,247	577	331	188	198	0	0	0
Unrealized losses on equity securities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities
Interest receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	482	-313	-391	-141	-38	33	-1,164	-568	0	0	0
Accounts receivable, net
67,658	89,720	37,798	32,288	38,376	45,233	45,814	61,762	28,618	22,846	25,311	14,198	21,295	8,998	1,623	12,492	2,805	13,682	19,681	10,345	11,691	9,740	14,609	-12,764	-6,825	-3,935	-5,948	16,116	-11,860	-21,512	19,709	20,542	47,960	35,676	185	-4,169	-5,194	-60,843	0	0	0
Inventories
17,504	32,693	16,862	2,217	-4,679	-6,739	14,335	1,686	11,192	-8,146	-10,808	-2,428	673	11,161	27,130	24,186	16,981	13,512	6,974	16,998	14,025	16,378	11,537	-8,170	-4,688	-10,674	-8,292	12,964	17,979	28,278	30,868	25,697	15,753	9,469	0	0	0	-	-	-	-
Prepaid expenses and other assets
13,150	-2,459	15,336	3,300	-4,364	14,567	-4,097	1,643	14,144	2,170	2,243	9,090	1,261	4,378	9,116	2,198	8,276	1,952	1,086	4,686	926	5,232	1,837	1,275	-469	1,817	1,856	394	2,991	1,551	-629	2,263	2,647	1,574	1,884	916	-4,855	-4,056	0	0	0
Lease liability
7,517	6,660	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Accounts payable and accrued liabilities
-	-	-	-	-	-	-	-	-	-	27,780	12,350	13,034	29,939	15,539	3,920	1,782	6,539	7,761	24,192	22,087	18,448	14,230	11,432	11,337	1,493	10,922	-2,577	5,200	3,082	4,238	18,318	15,172	27,265	11,307	12,932	10,469	6,287	0	0	0
Deferred revenue
-26,910	-33,600	-35,471	-33,232	-32,253	-33,913	-31,751	-27,977	-23,160	-16,878	-18,775	-23,305	-29,669	-36,631	-40,996	-39,985	-43,880	-48,376	-46,561	-39,254	-29,022	-23,181	-4,074	2,991	185	5,827	35,928	30,001	34,870	35,109	-2,282	-8,347	-1,085	8,437	18,433	36,448	19,325	-20,200	0	0	0
Other liabilities
57,494	47,451	63,379	43,647	50,976	34,757	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used by operating activities
-175,569	-163,737	-176,171	-126,641	-113,599	-203,536	-181,645	-178,760	-202,520	-118,900	-131,560	-154,918	-142,678	-96,971	-100,873	-109,843	-123,909	-133,203	-135,030	-106,262	-63,888	-59,999	-32,963	8,755	5,520	-1,110	42,835	-11,826	8,864	10,881	-76,409	-93,790	-142,313	-124,031	-108,897	-77,334	-47,340	6,808	0	0	0
Investing activities:
Purchases of securities
1,039,417	992,976	804,098	417,210	528,187	512,334	441,713	501,818	367,274	513,016	606,098	528,496	699,406	603,772	1,020,932	962,279	804,053	754,663	297,259	339,361	386,413	451,274	473,818	506,501	540,300	483,182	499,115	459,934	452,514	505,066	441,710	411,033	364,131	479,389	508,749	567,174	546,391	453,599	0	0	0
Proceeds from maturities of securities
810,500	786,000	503,001	408,700	406,200	398,722	385,721	450,522	590,522	653,200	688,500	643,000	733,000	699,800	636,500	659,800	430,600	367,200	433,100	448,300	462,700	504,100	437,700	505,400	537,500	480,700	501,500	411,300	391,000	425,151	424,857	469,900	486,200	498,959	535,228	494,075	459,475	443,256	0	0	0
Proceeds from sales of securities
19,996	0	0	14,869	91,883	140,352	140,352	125,483	48,469	60,056	60,056	60,056	60,056	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	10,824	10,825	5,825	5,825	0	0	0	0	-	-	-	-
Purchases of property and equipment
83,475	70,753	58,041	45,060	29,080	21,219	1,048	656	18,812	28,722	51,565	54,707	35,085	27,835	23,251	19,119	18,354	13,392	16,421	14,993	16,406	17,176	17,142	20,903	19,041	22,154	20,599	16,550	15,684	10,485	10,915	11,993	12,003	11,252	5,431	2,876	2,799	3,548	0	0	0
Acquisition of Cascadian Therapeutics, Inc., net of cash acquired
-	-	-	-	-	598,151	598,151	598,151	598,151	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-292,396	-277,729	-359,138	-38,701	-59,184	-592,630	-556,496	-566,277	-386,903	129,861	90,893	119,853	58,565	68,193	-407,683	-321,598	-366,802	-375,850	145,397	119,923	60,853	36,622	-53,071	-22,004	-21,841	-24,636	-18,404	-60,185	-72,199	-79,576	-16,945	47,138	110,127	2,554	15,536	-73,831	-87,368	-11,544	0	0	0
Financing activities:
Net proceeds from issuance of common stock
-	-	-	-	-	658,242	658,242	658,242	658,165	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168,053	168,053	168,053	168,118	0	0	0	0
Proceeds from exercise of stock options and employee stock purchase plan
84,111	89,151	64,627	70,167	70,086	55,165	67,216	48,978	42,381	41,311	37,778	40,081	40,333	35,196	25,511	17,898	21,069	27,763	26,921	26,521	20,794	16,188	16,673	24,448	26,199	35,199	40,167	38,883	44,926	35,724	36,180	27,615	24,125	19,931	14,642	13,416	9,727	7,377	0	0	0
Net cash provided by financing activities
632,802	637,842	613,318	70,167	70,163	713,407	725,458	707,220	700,546	41,311	37,778	40,081	40,333	35,196	25,511	544,516	547,687	554,381	553,539	26,521	20,794	16,188	16,673	24,448	26,199	35,199	40,167	38,883	44,926	35,724	36,180	27,615	24,060	187,984	182,695	181,469	177,845	7,377	0	0	0
Effect of exchange rate changes on cash and cash equivalents
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash and cash equivalents
164,846	196,376	78,009	-95,175	-102,620	-82,759	-12,683	-37,817	111,123	52,272	-2,889	5,016	-43,780	6,418	-483,045	113,075	56,976	45,328	563,906	40,182	17,759	-7,189	-69,361	11,199	9,878	9,453	64,598	-33,128	-18,409	-32,971	-57,174	-19,037	-8,126	66,507	89,334	30,304	43,137	2,641	0	0	0